Clinical Trial

Treating Schizophrenia by Correcting Abnormal Brain Development

Active, Not Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
The purpose of this study is to determine whether treatment with tiagabine (Gabitril) during the early course of schizophrenia can fundamentally correct the brain deficits associated with the disease. This study is funded by the National Institutes of Health.
Protocol Amendment History 12 amendments
This ClinicalTrials.gov record has been amended 12 times since 2005-09-12; most recent amendment 2025-01-23.
Status change: Recruiting → Active, Not Recruiting 2018-04-10
Trial Details
NCT Number NCT00179465
Lead Sponsor Beth Israel Deaconess Medical Center
Collaborators: Dartmouth-Hitchcock Medical Center
Conditions Schizophrenia
Enrollment 36 participants
Start Date 2003-11
Primary Completion 2026-09 (estimated)
Study Completion 2026-09 (estimated)
Updated on ClinicalTrials.gov 2025-01-27